Miraluma

Miraluma

A proprietary kit for preparing Technetium 99mTc Sestamibi for use in planar imaging as a 2nd-line post-mammography diagnostic tool for evaluating breast lesions in patients with an abnormal mammogram or a palpable breast mass.

On 27 June, 1997, the FDA issued a warning letter to DuPort Merck indicating that its advertising overstated Miraluma’s diagnostic efficacy.

Miraluma^™

Tc99m sestamibi Imaging A radionuclide used in planar imaging as a 2^nd-line post-mammography diagnostic tool for evaluating breast lesions in Pts with an abnormal mammogram or a palpable breast mass. See Mammography.